Prof G disagrees with NICE: Ocrelizumab IS value for money

In this video Rachel interviews Professor Gavin Giovannoni who is a Consultant Neurologist. The interview was filmed by Rob

Video transcript

Ocrelizumab was being reviewed by NICE as the first licensed treatment for Primary Progressive MS. Unfortunately, the drug hasn’t been recommended due to it currently already being available for Relapsing Remitting MS at a higher price. Prof G explains why he disagrees with NICE’s decision.

If you think it’s unfair that NICE aren’t recommending the first licensed drug for primary progressive MS, Gavin recommends writing to your MP. We’ve put together a template letter to download on this link.

MS Reporter: Rachel

Expert: Gavin Giovannoni, Consultant Neurologist, BARTS, London

More videos about Treatment category

Leave a Reply

Have you found this video useful? Please let us know by filling in this short survey.
Join the communityclose